Keybank National Association OH Has $20.34 Million Stake in Zoetis Inc. $ZTS

Keybank National Association OH trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 161,676 shares of the company’s stock after selling 16,574 shares during the period. Keybank National Association OH’s holdings in Zoetis were worth $20,342,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZTS. Brighton Jones LLC raised its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares during the period. Empowered Funds LLC grew its position in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC grew its position in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC grew its position in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co grew its position in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after purchasing an additional 506 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZTS. Citigroup began coverage on shares of Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price for the company. UBS Group decreased their target price on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research report on Tuesday. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $151.75.

Zoetis Stock Down 2.3%

Zoetis stock opened at $113.97 on Thursday. The company has a fifty day simple moving average of $120.17 and a 200 day simple moving average of $124.86. Zoetis Inc. has a 1-year low of $112.97 and a 1-year high of $172.23. The company has a market cap of $47.94 billion, a P/E ratio of 18.93, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the firm posted $1.40 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts anticipate that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.